Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on March 21, 2025
PharmAla Completes Shipment of LaNeo™ MDMA to the University of Washington
GlobeNewswire
·
March 21, 2025
TORONTO, March 21, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its …
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
GlobeNewswire
·
March 21, 2025
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 21 March 2025 at 15.00 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a …
Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (BlackRock, Inc.)
GlobeNewswire
·
March 21, 2025
ORION OYJ PÖRSSITIEDOTE / SUURIMMAT OSAKKEENOMISTAJAT -TIEDOTE 21.3.2025 KLO 15.00 Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (BlackRock, Inc.) Orion Oyj on saanut Arvopaperimarkkinalain 9. luvun 5 §:n …
TOMI Environmental Solutions Expands into Aquaculture with New Partner, Algafeed
GlobeNewswire
·
March 21, 2025
FREDERICK, Md., March 21, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, is pleased to announce the successful implementation of its …
Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference
GlobeNewswire
·
March 21, 2025
Grand Cayman, Cayman Islands, March 21, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced it has …
FibroBiologics to Present at The German-Nordic Joint Extracellular Matrix Meeting
GlobeNewswire
·
March 21, 2025
HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic …
BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025
GlobeNewswire
·
March 21, 2025
SUNNYVALE, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for …
Vireo Growth Inc. Files Definitive Information Circular and Provides Merger Transaction Updates
GlobeNewswire
·
March 21, 2025
– Filing of Definitive Information Circular and receipt of shareholder approval mark key milestones in closing process – – Missouri, Nevada and Utah transactions on track to close during the second quarter of 2025 – MINNEAPOLIS, March 21, 2025 (GLOBE …
OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category
GlobeNewswire
·
March 21, 2025
OXB honoured at 2025 CDMO Leadership Awards in 'Cell …
Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update
GlobeNewswire
·
March 21, 2025
Conference scheduled for Friday, March 21, 2025 at 10:00 a.m. Eastern time Woburn, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological …
23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test
GlobeNewswire
·
March 21, 2025
SAN FRANCISCO, March 21, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company with a mission to help people access, understand, and benefit from the human genome, today released a new report on the genetics of …
Anteris Reports One-Year Patient Outcomes for DurAVR® THV
GlobeNewswire
·
March 21, 2025
MINNEAPOLIS and BRISBANE, Australia, March 21, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris® or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting- …
FDA Approves New Prostate Cancer Imaging Agent Gozellix®
GlobeNewswire
·
March 21, 2025
MELBOURNE, Australia and INDIANAPOLIS, March 21, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug …
MedRisk’s 2025 Industry Trends Report Highlights Geographic Disparities and Cost-Saving Strategies in Physical Therapy for Workers’ Compensation
GlobeNewswire
·
March 21, 2025
KING OF PRUSSIA, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- MedRisk, a leading provider of solutions for the casualty claims industry, has released its 2025 Industry Trends Report, focusing on the critical role of early physical therapy (PT) in improving …
Yaqrit secures NIHR grant for pivotal trials of its liver support device, DIALIVE, for patients with liver failure
GlobeNewswire
·
March 21, 2025
Trial to assess intensive care liver support system across 13 UK centers, led by UCL, Royal Free, Kings College and Queen Elizabeth Birmingham Rapid co-primary endpoints measured over 10 and 28 days; readout Q1 2027 Aims to resolve life-threatening …
SANUWAVE Announces Record Quarterly Revenues: Q4 FY2024 Financial Results
GlobeNewswire
·
March 21, 2025
Q4 2024 revenues were $10.3 million, up 47% from Q4 2023. This was an all-time quarterly record for the Company. Full year 2024 revenues were $32.6 million, up 60% from full year 2023 revenues. This was an all-time annual record for the Company. Q4 2024 …
Chimerix Reports Fourth Quarter and Year End 2024 Financial Results
GlobeNewswire
·
March 21, 2025
New Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act (PDUFA) Action Date of August 18, 2025 Acquisition of Chimerix by Jazz Pharmaceuticals (Jazz) Expected to …
HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma
GlobeNewswire
·
March 21, 2025
— First and only EZH2 inhibitor approved by the NMPA — — HUTCHMED’s fourth product, and its first approval in hematological malignancies — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED …
Real People, Real Results: What Users Are Saying About Prime Biome
GlobeNewswire
·
March 21, 2025
ST. PETERSBURG, Fla., March 21, 2025 (GLOBE NEWSWIRE) -- Maintaining healthy skin often focuses on external care, but the Prime Biome supplement claims to rejuvenate skin from within. According to the manufacturers, skin health is directly linked to gut …
NeuroQuiet Reviews (Is It Safe And Legit to Use?) Tinnitus Relief Ingredients, Side Effects, And Benefits!
GlobeNewswire
·
March 21, 2025
AURORA, Colo., March 21, 2025 (GLOBE NEWSWIRE) -- NeuroQuiet is intricately designed to promote optimal ear health and support auditory functions and overall ear wellness. Its formula enhances brain performance and focuses on improving memory, clarity, and …